These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8622117)

  • 1. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients.
    Viganò A; Principi N
    J Chemother; 1995 Jun; 7 Suppl 2():95-101. PubMed ID: 8622117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
    Covi M; Velluti G
    J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
    Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
    J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections.
    Leal del Rosal P
    J Chemother; 1995 Jun; 7 Suppl 2():143-8. PubMed ID: 8622103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
    Beaucaire G
    J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the efficacy of isepamicin in the adult core clinical trial programme.
    Carbon C
    J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isepamicin versus amikacin in the treatment of urinary tract infection.
    Sturm W
    J Chemother; 1995 Jun; 7 Suppl 2():149-54. PubMed ID: 8622104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once daily isepamicin treatment in complicated urinary tract infections.
    Lee SS; Liu YC; Wann SR; Lin WR; Tsai TH; Lin HH; Chen YS; Yen MY
    J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the safety of isepamicin in adults.
    Blum D
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
    Petrikkos G; Giamarellou H; Tsagaraki C; Pefanis A
    J Chemother; 1995 Jun; 7 Suppl 2():161-4. PubMed ID: 8622106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies.
    Maltezou HC; Baka M; Gombakis N; Koliouskas DE; Kosmidou H; Malaka-Zafiriou E; Kafetzis DA
    Int J Antimicrob Agents; 2001 Oct; 18(4):383-6. PubMed ID: 11691573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isepamicin versus amikacin for the treatment of acute pyelonephritis in children.
    Kafetzis DA; Maltezou HC; Mavrikou M; Siafas C; Paraskakis I; Delis D; Bartsokas C
    Int J Antimicrob Agents; 2000 Feb; 14(1):51-5. PubMed ID: 10717501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics.
    Henriksson P; Svenningsen NW; Juhlin I; Haeger K
    Scand J Infect Dis Suppl; 1980; Suppl 23():155-9. PubMed ID: 7010546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amikacin in single daily doses in children with fever].
    Solórzano-Santos F; Miranda-Novales MG; Díaz-Peña R; Bernaldez-Ríos R; Díaz-Bensussen S; Rivera-Márquez H; Díaz-Ponce H
    Rev Invest Clin; 1996; 48(1):13-8. PubMed ID: 8815481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.